Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to explore its efficacy. We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural me...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of clinical oncology Ročník 20; číslo 16; s. 3533
Hlavní autori:	Hughes, Andy, Calvert, Paula, Azzabi, Ashraf, Plummer, Ruth, Johnson, Rob, Rusthoven, Jim, Griffin, Melanie, Fishwick, Kevin, Boddy, Alan V, Verrill, Mark, Calvert, Hilary
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 15.08.2002
Predmet:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Area Under Curve Carboplatin - administration & dosage Dose-Response Relationship, Drug Female Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Hematologic Diseases - chemically induced Humans Male Maximum Tolerated Dose Mesothelioma - drug therapy Mesothelioma - mortality Middle Aged Pemetrexed Pleural Neoplasms - drug therapy Pleural Neoplasms - mortality Survival Rate
ISSN:	0732-183X
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!